Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
- 1 June 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 19 (3), 363-375
- https://doi.org/10.1007/s40257-017-0337-2
Abstract
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.Funding Information
- National Cancer Institute (Cancer Center Support Grant P30 CA008748)
This publication has 110 references indexed in Scilit:
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH StudyThe American Journal of Gastroenterology, 2013
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseAnnals Of The Rheumatic Diseases, 2012
- Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIFOncogene, 2012
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics registerArthritis Care & Research, 2010
- TH17 cells in tumour immunity and immunotherapyNature Reviews Immunology, 2010
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnnals Of The Rheumatic Diseases, 2009
- Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals Of The Rheumatic Diseases, 2008
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006